278 related articles for article (PubMed ID: 23373620)
1. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J
J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
3. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
7. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
8. Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.
Mrdovic I; Savic L; Krljanac G; Asanin M; Perunicic J; Antonijevic N; Lasica R; Marinkovic J; Kocev N; Vasiljevic Z
Int J Cardiol; 2013 Aug; 167(4):1632-7. PubMed ID: 22626838
[TBL] [Abstract][Full Text] [Related]
9. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
10. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
[TBL] [Abstract][Full Text] [Related]
12. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Xia JG; Qu Y; Shen H; Liu XH
Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
15. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
17. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
18. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM
Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
